Decreasing maltose metabolism has been reported in literature to improve blood glucose after sugar challenge and reduction in maltase activity is a desired effect in anti-diabetic therapies such as trigonelline [74, 75]IBD was associated with increases in starch and beta-galactosidase activity. Here, GLB1 is linked to inflammatory bowel disease.